AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 66.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 297,576 shares of the company’s stock after buying an additional 118,359 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in AstraZeneca were worth $23,098,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Brookstone Capital Management purchased a new stake in shares of AstraZeneca during the first quarter worth approximately $315,000. Wealthcare Advisory Partners LLC increased its position in shares of AstraZeneca by 9.7% in the first quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock valued at $416,000 after buying an additional 543 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in AstraZeneca by 57.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 181,601 shares of the company’s stock worth $12,303,000 after purchasing an additional 66,181 shares in the last quarter. Kathmere Capital Management LLC increased its position in AstraZeneca by 4.5% during the 1st quarter. Kathmere Capital Management LLC now owns 4,065 shares of the company’s stock worth $275,000 after purchasing an additional 175 shares in the last quarter. Finally, Founders Financial Securities LLC boosted its stake in AstraZeneca by 8.1% in the 1st quarter. Founders Financial Securities LLC now owns 11,982 shares of the company’s stock worth $812,000 after buying an additional 898 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $75.05 on Friday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market capitalization of $232.69 billion, a PE ratio of 36.79, a PEG ratio of 1.43 and a beta of 0.46. The business’s 50 day moving average is $80.40 and its 200-day moving average is $78.51. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.01. The firm had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS. Sell-side analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.